JOURNAL of
ONCOLOGICAL
SCIENCES

REVIEW ARTICLE

Stem Cells and Psyche: Perspectives and a Review of the Literature
Received Date : 16 Oct 2019
Accepted Date : 03 Apr 2020
Available Online : 24 Jun 2020
Doi: 10.37047/jos.2019-71899 - Article's Language: EN
J Oncol Sci.2020;6(2):103-18
This is an open access article under the CC BY-NC-ND license
ABSTRACT
In the 20th century, bone marrow transplantation evolved great expectations in the medical community and gained enormous popularity in society ever since. With the discovery of other stem cell sources, the designation of ‘bone marrow transplantation’ was replaced with ‘stem cell transplantation’ in clinical practice. The adaptation and response of patients, patient relatives, custodians, donors, and healthcare providers to current treatment approaches developed a serious psychosocial entity. Moreover, the psychosocial entity can be further complicated by various organic mental diseases, which may arise as a consequence of serious illnesses and burdensome treatments. An independent area of expertise is essential to evaluate, diagnose, and solve all these problems with a scientific approach. Correlating the organic and psychological components of the patient’s condition, facilitating communication between patients, doctors, families, and hospital systems, and counseling-liaison work have emerged as one of the most challenges of psychiatric skills. This necessitated the presence of a Consultation- Liaison Psychiatry (CLP) that undertakes this mission. First, basic principles and associated features of hematopoietic stem cell transplantation (HSCT) from the perspective of the clinician, patient relatives, and custodians, and expectations will be discussed. Afterward, the transplant unit from the viewpoint of the patient relatives and custodians and the perspective of child psychiatry and symptoms of burnout in an HSCT team will be discussed. Thereafter, the experiences and difficulties faced by the HSCT team in being a researcher and a student will be analyzed. Finally, ethical and legal issues pertaining to our country and the world will be discussed. We hope that this review will provide a scientific interpretation to the healthcare providers who experience the same difficulties in many different areas.
KAYNAKLAR
  1. Spangrude GJ. Stem Cells and Tissue Regeneration. When is a stem cell really a stem cell? Bone Marrow Transp. August 2003;32:7-11. [Crossref]  [PubMed] 
  2. Suda T, Takubo K, Semenza GL. Metabolic regulation of hematopoietic stem cells in the hypoxic niche. Cell Stem Cell. 2011;9(4):298-310. [Crossref]  [PubMed] 
  3. Ray P, De A, Yaghoubi S, Khanna A. Application of adult stem cells in medicine. Stem Cells International. 2015:258313 [Crossref]  [PubMed]  [PMC] 
  4. Thomas ED, Lochte Jr HL, LU Wc, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257(11):491-496. [Crossref]  [PubMed] 
  5. EBMT. Transplant activity survey. https://www.ebmt.org/registry/transplant-activity-survey [Accessed 04 August 2020].
  6. Passweg JR, Baldomero H, Bader P et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40.000 transplants annually. Bone Marrow Transplant. 2016;51(6): 786-92. [Crossref]  [PubMed]  [PMC] 
  7. Passweg JR, Baldomero H, Bader P et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 european society for blood and marrow transplant activity survey report. Bone Marrow Transplant. 2017;52(6):811-817. [Crossref]  [PubMed]  [PMC] 
  8. Anasetti C. Use of alternative donors for allogeneic stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2015;2015: 220-4. [Crossref]  [PubMed] 
  9. Sabo BM. Compassionate presence: the meaning of hematopoietic stem cell transplant nursing. Eur J Oncol Nurs. 2011;15(2):103-111. [Crossref]  [PubMed] 
  10. Cooke L, Gemmill R, Kravits K, Grant M. Psychological issues of stem cell transplant. Semin Oncol Nurs. 2009;25(2):139-50. [Crossref]  [PubMed]  [PMC] 
  11. Lederberg MS. The family of the cancer patient. In: Holland J, editor. Psycho-oncology. New York, Oxford: Oxford University Press; 1998. p.981-993. https://www.ncbi.nlm.nih.gov/books/NBK4011/
  12. Carr A. Family Therapy: Concepts, Process and Practice. 3rd edition 2012. Wiley-Blackwell Interscience.
  13. Minuchin S, Rossmann BI, Baker K. Psychosomatic Families: Anorexia Nervosa in Context. 1st ed. Cambridge: Cambridge Harvard University Press; 1978:351.
  14. Kotkamp-Mothers N, Slawinsky D, Hindermann S, Strauss B. Coping and psychological well being in families of elderly cancer patients. Crit Rev Oncol Haematol. 2005;55(3): 213-229. [Crossref]  [PubMed] 
  15. Cupit MC, Duncan C, Savani BN, Hashmi SK. Childhood to adult transition and long-term follow-up after blood and marrow transplantation. Bone Marrow Transplant. 2016;51(2):176-181. [Crossref]  [PubMed] 
  16. Ahomäki R, Gunn ME, Madanat-Harjuoja LM, Matomäki J, Malila N, Lähteenmäki PM. Late psychiatric morbidity in survivors of cancer at a young age: a nationwide registry-based study. Int J Canc. 2015;137(1):183-192. [Crossref]  [PubMed] 
  17. Bougea A, Kleisarchakis MK, Gioka V, Belegri SA. Relationship of οccupational stress parameters with burn-out and perceived stres. Psychiatriki. 2015;26(2):106-115. [PubMed] 
  18. Zanatta AB, De Lucca SR. Prevalence of Burnout syndrome in health professionals of an onco-hematological pediatric hospital. Rev Esc Enferm USP. 2015;49(2):253-260. [Crossref]  [PubMed] 
  19. Panagioti M, Panagopoulou E, Bower P, et al. Controlled interventions to reduce burnout in physicians a systematic review and meta-analysis. JAMA Intern Med. 2017;177(2):195-205. [Crossref]  [PubMed] 
  20. Graham J, Potts HWW, Ramirez AJ. Stress and burnout in doctors. The Lancet. 2002;360(9349):1975-1976. [Crossref]  [PubMed] 
  21. Martini S, Arfken CL, Churchill A, Balon R. Burnout comparison among residents in different medical specialties. Academic Psychiatry. 2004;28(3):240-242. [Crossref]  [PubMed] 
  22. Lee FJ, Stewart M, Brown JB. Stress, burnout, and strategies for reducing them: what's the situation among Canadian family physicians? Can Fam Physician. 2008;54(2):234-235. [PubMed] 
  23. West CP, Dyrbye LN, Erwin PJ, Shanafelt TD. Interventions to prevent and reduce physician burnout: a systematic review and meta-analysis. The Lancet. 2016;388(10057):2272-2281. [Crossref]  [PubMed] 
  24. Shanafelt TD, Boone S, Tan L, et al. Burnout and satisfaction with work-life balance among US physicians relative to the general US population. Arch Intern Med. 2012;172(18):1377-1385. [Crossref]  [PubMed] 
  25. Whitford B, Nadel AL, Fish JD. Burnout in pediatric hematology/oncology-time to address the elephant by name. Pediatr Blood Cancer. 2018;65(10):e27244. [Crossref]  [PubMed] 
  26. Neumann JL, Mau LW, Virani S, et al. Burnout, moral distress, work-life balance, and career satisfaction among hematopoietic cell transplantation professionals. Biol Blood Marrow Transplant. 2018;24(4):849-860. [Crossref]  [PubMed] 
  27. Hlubocky FJ, Back AL, Shanafelt TD. Addressing burnout in oncology: why cancer care clinicians are at risk, what individuals can do, and how organizations can respond. Am Soc Clin Oncol Educ Book. July 2016;35:271-279. [Crossref]  [PubMed] 
  28. Shanafelt TD, Noseworthy JH. Executive Leadership and Physician Well-being: nine organizational strategies to promote engagement and reduce burnout. Mayo Clinic Proc. 2017;92(1):129-146. [Crossref]  [PubMed] 
  29. Fagan MB. Philosophy of stem cell biology - an introduction. Philosophy Compass. 2013;8(12):1147-1158. [Crossref] 
  30. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676. [Crossref]  [PubMed] 
  31. Gurdon JB. The egg and the nucleus: a battle for supremacy (Nobel Lecture). Angew Chem Int Ed Engl. 2013;52(52):13890-13899. [Crossref]  [PubMed] 
  32. Yamanaka S. The winding road to pluripotency (Nobel Lecture). Angew Chem Int Ed Engl. 2013;52(52):13900-13909. [Crossref]  [PubMed] 
  33. Van Servellen A, Oba I. Stem cell research: trends and perspectives on the evolving international landscape. Research Trends. 2014;36. https://www.researchtrends.com/issue-36-march-2014/stem-cell-research/ [Accessed 04 August 2020].
  34. Atilla E, Kilic P, Gurman G. Cellular therapies: day by day, all the way. Transfus Apher Sci. 2018;57(2):187-196. [Crossref]  [PubMed] 
  35. Ham RMTT, Hoekman J, Hövels AM, Broekmans AW, Leufkens HGM, Klungel OH. Challenges in advanced therapy medicinal product development: a survey among companies in europe. Mol Ther Methods Clin Dev. October 2018;11:121-130. [Crossref]  [PubMed]  [PMC] 
  36. Dalal AR. Philosophy of organ donation: Review of ethical facets. World J Transplant. 2015;5(2):44-51. [Crossref]  [PubMed]  [PMC] 
  37. Zink S, Zeehandelaar R, Wertlieb S. Presumed versus expressed consent in the US and internationally. Virtual Mentor. 2005;7(9):610-614. [Crossref]  [PubMed] 
  38. FDA. Guidance For Industry. Eligibility Determination For Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). 2007:1-70 https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/UCM091345.pdf [Accessed 05 February 2019].
  39. Official Journal of the European Union. Commission Directive 2006/17/EC of 8 February 2006 Implementing Directive 2004/23/EC of the European Parliament and of the Council as Regards Certain Technical Requirements for the Donation, Procurement and Testing of Human Tissues and Cells. February 2006;102:38-40. https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:038:0040:0052:EN:PDF [Accessed 04 August 2020].
  40. Héma-Québec. Annual Report 2014-2015. 2015:1-105. http://www.hema-quebec.qc.ca/userfiles/file/media/anglais/publications/RA_2014-2015_ANG(2).pdf 2015 [Accessed 04 August 2020].
  41. T.C. Cumhurbaşkanlığı Mevzuat Bilgi Sistemi. İnsan Doku ve Hücreleri ve Bunlarla İlgili Merkezlerin Kalite ve Güvenliği Hakkında Yönetmelik. 2010. https://www.mevzuat.gov.tr/mevzuat?MevzuatNo=14389&MevzuatTur=7&MevzuatTertip=5 [Accessed 04 August 2020].
  42. European Commission. Competent Authorities for Tissues and Cells. https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/competentauthorities_tissues_cells_en.pdf [Accessed 08 February 2019].
  43. T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü. https://shgm.saglik.gov.tr/; [Accessed 08 February 2019].
  44. Turkish Medicines and Medical Devices Agency. https://www.titck.gov.tr/ [accessed 08 February 2019].
  45. T.C. Cumhurbaşkanlığı Mevzuat Bilgi Sistemi. Türk Ceza Kanunu. 2004. http://www.mevzuat.gov.tr/MevzuatMetin/1.5.5237-20150327.pdf [Accessed 08 February 2019].
  46. T.C. Cumhurbaşkanlığı Mevzuat Bilgi Sistemi. Organ ve Doku Alınması, Saklanması, Aşılanması ve Nakli Hakkında Kanun. 1979. http://www.mevzuat.gov.tr/MevzuatMetin/1.5.2238.pdf [Accessed 08 February 2019].
  47. T.C. Cumhurbaşkanlığı Mevzuat Bilgi Sistemi. Organ ve Doku Nakli Hizmetleri Yönetmeliği. 2012. http://www.mevzuat.gov.tr/Metin.Aspx?MevzuatKod=7.5.15860&MevzuatIliski=0&sourceXmlSearch=organ%20ve [Accessed 08 February 2019].
  48. T.C. Cumhurbaşkanlığı Mevzuat Bilgi Sistemi. İnsan Doku ve Hücre Ürünlerinin Ruhsatlandırılması ve Bu Ürünlerin Üretim, İthalat, İhracat, Depolama ve Dağıtım Faaliyetlerini Yürüten Merkezler Hakkında Tebliğ. 2014. https://www.mevzuat.gov.tr/mevzuat?MevzuatNo=19549&MevzuatTur=9&MevzuatTertip=5 [Accessed 04 August 2020].
  49. Türk Tabipler Birliği. Embriyonik Kök Hücre Araştırmaları Hakkında Sağlık Bakanlığı Genelgesi. 2005. http://www.ttb.org.tr/mevzuat/index.php?option=com_content&view=article&id=347:embron-k-hre-arairmalari-hakkinda-saik-bakanli-genelges&catid=3:tebligenelge&Itemid=35 [Accessed 08 February 2019].
  50. Türk Tabipler Birliği. Kök Hücre Araştırmaları Hakkında Sağlık Bakanlığı Genelgesi (Mayıs 2006). 2006. http://www.ttb.org.tr/mevzuat/index.php?option=com_content&task=view&id=387&Itemid=35 [Accessed 08 February 2019].
  51. T.C. Sağlık Bakanlığı Sağlık Hizmetleri Genel Müdürlüğü. Kök Hücre Çalışmaları Hakkında Sağlık Bakanlığı Genelgesi. 2018. https://dosyamerkez.saglik.gov.tr/Eklenti/15612,kok-hucre-calismalari-genelgepdf.pdf?0 [Accessed 08 February 2019].
  52. T.C. Cumhurbaşkanlığı Mevzuat Bilgi Sistemi. İlaç ve Biyolojik Ürünlerin Klinik Araştırmaları Hakkında Yönetmelik. 2013. http://www.mevzuat.gov.tr/Metin.Aspx?MevzuatKod=7.5.17285&MevzuatIliski=0 [Accessed 08 February 2019].
  53. Turkish Medicines and Medical Devices Agency. Regulation on Manufacturing Plants of Medicinal Products for Human Use. 2013. https://titck.gov.tr/storage/legislation/vyAfm1iR.pdf [Accessed 08 February 2019].
  54. Turkish Medicines and Medical Devices Agency. Regulation on the Registration of Medicinal Products for Human Use. 2005. https://titck.gov.tr/storage/legislation/QEv7VEBH.pdf [Accessed 08 February 2019].
  55. Türkiye İlaç ve Tıbbi Cihaz Kurumu. İleri Tedavi Tıbbi Ürünleri Kılavuz Taslağı. 2018. https://www.titck.gov.tr/mevzuat/ileri-tedavi-tibbi-urunleri-kilavuz-taslagi-08112018173059 [Accessed 04 August 2020].
  56. FDA. Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use. 2017. https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/cellularandgenetherapy/ucm585403.pdf [Accessed 08 February 2019].
  57. Official Journal of the European Union. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 an Advanced Therapy Medicinal Products and Amending Directive 2001/83/EC and Regulation (EC) No 726/2004. 2007:121-137. https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32007R1394&from=EN [Accessed 04 August 2020].
  58. TÜBİTAK. Ulusal Bilim ve Teknoloji Politikaları 2003-2023 Strateji Belgesi. 2004:1-137. https://www.tubitak.gov.tr/tubitak_content_files/vizyon2023/Vizyon2023_Strateji_Belgesi.pdf [Accessed 08 February 2019].
  59. T.C. Sağlık Bakanlığı. Stratejik Plan 2013-2017. 2012:1-165. http://dosyasb.saglik.gov.tr/Eklenti/9843,saglik-bakaligi-stratejik-plan--2013-2017pdf.pdf [Accessed 08 February 2019].
  60. T.C. Bilim, Sanayi ve Teknoloji Bakanlığı. Türkiye Biyoteknoloji Stratejisi ve Eylem Planı (2015-2018). 2015. https://www.sanayi.gov.tr/handlers/DokumanGetHandler.ashx?dokumanId=017882b9-01fe-4b8c-86dd-b5d9ca996e60 [Accessed 04 August 2020]. http://www.tuba.gov.tr/tr/duyurular/turkiye-biyoteknoloji-stratejisi-ve-eylem-plani-2015- 2018
  61. TÜBİTAK. Ar-Ge Strateji Belgesi Sonuçları. 2018. https://ttm.trakya.edu.tr/news/1000-programi-ar-ge-strateji-belgesi-hazirlatilmasi-ve-uygulanmasi-cagrisi-sonuclari-aciklandi [Accessed 04 August 2020].
  62. CNN Türk. Kök hücre tedavisi ile eklem ağrılarına son. 2018. https://www.cnnturk.com/saglik/kok-hucre-tedavisi-ile-eklem-agrilarina-son?page=1 [Accessed 08 February 2019].
  63. Takvim. Kök hücre tedavisiyle Ece'ye yeni akciğer. 2015. https://www.takvim.com.tr/guncel/2015/10/30/kok-hucre-tedavisiyle-eceye-yeni-akciger [Accessed 04 August 2020].
  64. Gazete Vatan. Kök hücre umudu. 2017. http://www.gazetevatan.com/kok-hucre-umudu--1130819-gundem/ [Accessed 08 February 2019].
  65. Hürriyet. Kök hücrelerimiz ile yüz ve cilt gençleştirme. 2016. https://www.hurriyet.com.tr/kelebek/saglik/kok-hucrelerimiz-ile-yuz-ve-cilt-genclestirme-40099554 [Accessed 04 August 2020].